SCHEMBL14320792

SCHEMBL14320792

CN1CCN(c2ccc(Nc3nc(-c4ccsc4)nc4cn[nH]c34)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 8/20 0.65
SYK P43405 9/20 0.54
MAPKAPK2 P49137 1/20 0.47
FGFR1 P11362 2/20 0.44
AURKA O14965 2/20 0.44
AURKB Q96GD4 2/20 0.44
BTK Q06187 2/20 0.44
CHEK1 O14757 1/20 0.44
DAPK3 O43293 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
PAK4 O96013 1/20 0.44
ABL1 P00519 1/20 0.44
NTRK1 P04629 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
CSF1R P07333 1/20 0.44
RET P07949 1/20 0.44
IGF1R P08069 1/20 0.44
MET P08581 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320315 0.91 JAK2 (0.61) JAK2SYKMAPKAPK2BTKHTR2A
SCHEMBL14321127 0.90 JAK2 (0.61) JAK2SYKBTKPDGFRBPDGFRA
SCHEMBL14320420 0.90 JAK2 (0.60) JAK2SYKBTKHTR2AHTR2C
SCHEMBL14320718 0.90 JAK2 (0.60) JAK2SYKMAPKAPK2BTKHTR2A
SCHEMBL14321220 0.89 JAK2 (0.62) JAK2SYKALK
SCHEMBL14320457 0.88 JAK2 (0.52) JAK2SYKFGFR1AURKAAURKB
SCHEMBL14320662 0.88 JAK2 (0.51) JAK2SYKMAPKAPK2FYNJAK3
SCHEMBL14320583 0.87 JAK2 (0.62) JAK2SYKAURKAAURKBJAK3
SCHEMBL13735503 0.85 JAK2 (0.51) JAK2SYKIGF1RPDGFRBPDGFRA
SCHEMBL14320443 0.85 JAK2 (0.48) JAK2SYKFGFR1AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK JAK2 60/4885SYK 11/4885MAPKAPK2 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.